215 related articles for article (PubMed ID: 8040892)
1. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
2. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M
Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
[TBL] [Abstract][Full Text] [Related]
3. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
Supino R; Polizzi D; Pavesi R; Pratesi G; Guano F; Capranico G; Palumbo M; Sissi C; Richter S; Beggiolin G; Menta E; Pezzoni G; Spinelli S; Torriani D; Carenini N; Dal Bo L; Facchinetti F; Tortoreto M; Zunino F
Oncology; 2001; 61(3):234-42. PubMed ID: 11574780
[TBL] [Abstract][Full Text] [Related]
4. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of anthrapyrazoles derivatives as potential antitumor agents.
Wang J; Zhao H; Luo Z; Wang Z; Zhang Y; Zhao J
Med Chem; 2014; 10(8):772-7. PubMed ID: 24773347
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
Solary E; Leteurtre F; Paull KD; Scudiero D; Hamel E; Pommier Y
Biochem Pharmacol; 1993 Jun; 45(12):2449-56. PubMed ID: 8392342
[TBL] [Abstract][Full Text] [Related]
8. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.
Showalter HD; Fry DW; Leopold WR; Lown JW; Plambeck JA; Reszka K
Anticancer Drug Des; 1986 Apr; 1(2):73-85. PubMed ID: 2453196
[TBL] [Abstract][Full Text] [Related]
9. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.
Fisher GR; Patterson LH
Cancer Chemother Pharmacol; 1992; 30(6):451-8. PubMed ID: 1394801
[TBL] [Abstract][Full Text] [Related]
10. New drugs. The anthrapyrazoles.
Gogas H; Mansi JL
Cancer Treat Rev; 1996 Nov; 21(6):541-52. PubMed ID: 8599804
[No Abstract] [Full Text] [Related]
11. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).
Fry DW; Boritzki TJ; Besserer JA; Jackson RC
Biochem Pharmacol; 1985 Oct; 34(19):3499-508. PubMed ID: 2413861
[TBL] [Abstract][Full Text] [Related]
12. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones.
de Isabella P; Palumbo M; Sissi C; Carenini N; Capranico G; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC; Zunino F
Biochem Pharmacol; 1997 Jan; 53(2):161-9. PubMed ID: 9037248
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
15. Azatoxin derivatives with potent and selective action on topoisomerase II.
Leteurtre F; Sackett DL; Madalengoitia J; Kohlhagen G; MacDonald T; Hamel E; Paull KD; Pommier Y
Biochem Pharmacol; 1995 May; 49(9):1283-90. PubMed ID: 7763310
[TBL] [Abstract][Full Text] [Related]
16. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
17. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation.
Frank P; Novak RF
Biochem Biophys Res Commun; 1986 Nov; 140(3):797-807. PubMed ID: 3778486
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
Smith PJ; Morgan SA; Fox ME; Watson JV
Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
[TBL] [Abstract][Full Text] [Related]
19. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox ME; Smith PJ
Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance.
Solary E; Ling YH; Perez-Soler R; Priebe W; Pommier Y
Int J Cancer; 1994 Jul; 58(1):85-94. PubMed ID: 8014019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
